Iradimed (IRMD) Common Equity (2013 - 2026)

Iradimed (IRMD) has reported Common Equity for 14 consecutive years, with $101.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 7.9% year-over-year to $101.7 million in Q2 2026; TTM through Jun 2026 was $101.7 million, a 7.9% increase from a year earlier, with the FY2025 full-year figure at $94.6 million, up 8.98% from the prior year.
• Common Equity was $101.7 million for Q2 2026 at Iradimed, up from $98.5 million in the prior quarter.
• Over five years, Common Equity peaked at $101.7 million in Q2 2026 and troughed at $62.5 million in Q1 2022.
• A 5-year average of $80.8 million and a median of $77.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity decreased 3.06% in 2023 and gained 21.56% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $73.7 million in 2022, then decreased by 3.06% to $71.4 million in 2023, then advanced by 21.56% to $86.8 million in 2024, then climbed by 8.98% to $94.6 million in 2025, then climbed by 7.54% to $101.7 million in 2026.
• The last three Common Equity figures came in at $101.7 million (Q2 2026), $98.5 million (Q1 2026), and $94.6 million (Q4 2025), per Business Quant data.